Genmab — Juli 2018

[hda]

Friday after Committee plenary

[hda]

http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/document_listing/document_listing_000378.jsp&mid=WC0b01ac0580028d2a

[E_L]

Trial represents ‘bold move’ for treatment of newly diagnosed myeloma - https://www.healio.com/hematology-oncology/myeloma/news/online/{1ebabaf8-6883-4567-8253-bc4ce2e72ecf}/trial-represents-bold-move-for-treatment-of-newly-diagnosed-myeloma

[E_L]

from Seattle Genetics Q2 2018 Results http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=RssLanding&cat=news&id=2360357

[E_L]

Tisotumab Vedotin (TV) Program Activities
• Metastatic Cervical Cancer Trial Initiated: Seattle Genetics and Genmab initiated a phase 2 trial called innovaTV 204 in patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment. The trial will enroll approximately 100 patients and is intended to potentially support registration under the FDA's accelerated approval pathway.

[E_L]

• Solid Tumor Trial Initiated: Seattle Genetics and Genmab initiated a phase 2 clinical trial called innovaTV 207 in several types of solid tumors. The trial is intended to inform a potential broad development program.

[E_L]

we know this offcourse

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen.

[polle1]

God morgen

[GeorgeBest]

God morgen til dagen hvor ALCYONE bliver indstillet til 1. linie godkendelse i Europa.......forhåbentlig....:-)

[transalp]

Go morgen..

[Plimsoller]

Go' morgen

[bibob]

Ja GB. Det ville være en god fredags nyhed.

[JKY_VH]

Enig, det ville være dagens gode nyhed og god morgen;-)

[E_L]

Seattle Genetics (SGEN) Q2 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4190986-seattle-genetics-sgen-q2-2018-results-earnings-call-transcript?part=single

[E_L]

do i need to copy/paste, or can you search for tisotumab yourselves...?

[nsrafk]

c/p is best service

[E_L]

lol, shoudn´t have asked, stupid

[E_L]

Our third late-stage program is tisotumab vedotin. which we're developing with Genmab. We've achieved two recent milestones. We've dosed the first patient in a pivotal trial for women with recurrent or metastatic cervical cancer. And we started a Phase 2 basket trial evaluating tisotumab vedotin in other solid tumors. These trials are intended to support an initial accelerated approval pathway in cervical cancer and inform opportunities to broaden the program.